# Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone

> **NCT05509374** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 33 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib 56 MG [Kyprolis]
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05509374
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-28
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2022-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05509374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05509374, "Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05509374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*